Dr. Hartwell is an entrepreneur with a strong record of successful business startups, and is a co-inventor of FS2 and AI-001 cell therapy. Prior to undertaking his Ph.D., Dr. Hartwell cofounded ATS Biotech Inc., an advanced, biomedical wound care (medical device) company specializing in the development and manufacture of medical devices that are currently being developed in the United States, none of which have any competitive standing relative to BirchBioMed products. As a university and workshop lecturer with first-hand experience in FDA, EU, HC, CFDA and Japan Regulatory filings for drug products, medical devices and natural health products, Dr. Hartwell brings a wealth of experience to BirchBioMed’s regulatory affairs and medical product manufacturing. Dr. Hartwell received his Ph.D. in Experimental Medicine at UBC, receiving the Vancouver Coastal Health Research Institute Award for Top Graduating Doctoral Student and Rising Star in Research. Dr. Hartwell has published over 25 peer-reviewed articles, 26 presentation abstracts, and 4 patents. As a founder of BirchBioMed, Dr. Hartwell maintains a strong research and development relationship with UBC, managing teams and conducting research that is of mutual benefit for Birch and UBC projects. As an active member of the academic and life sciences community, Dr. Hartwell continues to lecture for the UBC Department of Surgery, leads investigator-forums and workshops at major local, national and international conferences, and is an active Reviewer for several Publications in the fields of biomaterials, pharmacology, cell biology, and tissue engineering. Prior to receiving his Ph.D., Dr. Hartwell attended the University of Ottawa, graduating with honours in Biochemistry. Shortly after graduating, Dr. Hartwell conducted research in Free Radicals in Medicine at the National University of Singapore under world-renowned researcher and industry leader, Professor Barry Halliwell.